| Invested through |
|
|---|---|
| Asset Classes | Listed equity |
| Impact strategy | Impact Equities and Bonds |
| ISIN code | US2166485019 |
| Industry group | Health care equipment & services |
| Aligned with SDGs |
Cooper is a global medical devices company that operates in two segments: CooperVision and CooperSurgical. CooperVision provides vision care products, mostly (soft) contact lenses and products for practitioner support. CooperVision also has a small but rapidly growing product suite to improve myopia in children. CooperSurgical provides medical devices, diagnostic products, and surgical instruments and accessories that advance the health of women, babies and families.
Cooper was originally a challenger in an established market, but through acquisitions and a leading position in silicon hydro gel lenses, the company has established a strong competitive position. Cooper was founded in 1958 and is headquartered in San Ramon, California, US.
Investment rationale
CooperVision (CVI) is one of the world’s leading manufacturers of soft contact lenses, featuring advanced materials and optics. CVI has been among the early users of silicone hydrogel technology which has some health benefits compared to traditional contact lens materials, including a lower risk of eye infections. CVI has been an early innovator in the field of myopia (nearsightedness) as the company has invented a myopia management contact lens called MiSight. The objective of MiSight is to correct and halt the progression of myopia in children, protecting their eye health in the future, as a higher level of myopia can lead to more severe conditions including glaucoma, cataracts and retinal detachment which can result in blindness.
CooperSurgical (CSI) focuses on women’s and babies' health, covering products and services used primarily by obstetricians and gynaecologists. CSI's fertility and reproductive genomics product suite plays an important role in fertility clinics worldwide.
Alignment with Triodos Transitions:
In total, 100% of revenues is aligned with the Wellbeing Transition and 5% of revenues is aligned with the Societal Transition. The contribution to the Societal Transition comes from 5% of revenues related to the impact objective Socioeconomic Advancement & Empowerment. The contribution to the Wellbeing Transition comes from 100% of revenues related to the impact objective Health Care.